Results
1 -
10 of
26Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption, Osteoporosis International Review of the guideline of the American College of Physicians on the treatment of osteoporosis, Osteoporosis International Anabolic agents: what is beyond osteoporosis?, Osteoporosis International Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting, Osteoporosis International Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial, Osteoporosis International World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Oral Communication Abstracts, Osteoporosis International World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2017): Plenary Lectures Abstracts, Osteoporosis International Neue Antiosteoporotika am Horizont, Zeitschrift f??r Rheumatologie Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats, Calcified Tissue International Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies, Calcified Tissue International